Original vs generic drugs in treatment of chronic myeloid leukaemia
Journal Title: OncoReview - Year 2014, Vol 4, Issue 3
Abstract
The beginning of the twenty-first century saw a breakthrough in haematology, oncology and general medicine driven by the introduction of imatinib (Glivec) to the treatment of chronic myeloid leukaemia. For the first time, a neoplastic disease was successfully treated by a therapy targeting the genetic cause of the disease. At present, targeted therapy based on imatinib is the first one to enter a new stage which is the launch of generic drugs. Poland is the first country in the European Union which, from the beginning of July 2014, introduced generic imatinib. Hence, there is no reliable data on its use except for results from bioequivalence tests. The only data available comes from developing countries where other preparations are used, without reliable bioequivalence studies. However, all generic drugs of imatinib registered in Poland have successfully passed such tests. Undoubtedly, it is necessary to appropriately monitor patients with chronic myeloid leukaemia receiving generic drugs in order to ensure their safety and provide information to other countries where therapy based on generic drugs will be introduced in the following years.
Authors and Affiliations
Patrycja Rusicka
Keywords
Related Articles
- EP ID EP67764
- DOI -
- Views 193
- Downloads 0
Recurrent invasive pulmonary aspergillosis or breakthrough fungal infection in a child after haploidentical hematopoietic stem cell transplantation
Invasive fungal infections (IFI) are devastating and life threatening infections affecting especially immunocompromised patients. We report on a case of a 14-year-old boy with myelodysplastic syndrome (MDS), after haplo...
“Life-saving” inappropriate implantable cardioverter-defibrillator shocks in a cancer patient
Impaired left ventricular ejection fraction (LV EF) in patients with cancer can disqualify them from targeted antineoplastic treatment. We present the case of 63-year-old male with gastric cancer treated palliatively, wi...
A role of JAK in the pathogenesis of Philadelphia negative myeloproliferative neoplasms. Target therapy possibilities
In recent years a significant progress has been made in understanding of the pathogenesis of myeloproliferative neoplasms, especially the one with mutation in JAK2 gene. In 2005 several study groups confirmed the presenc...
Maintenance chemotherapy with pemetrexed in patients with malignant pleural mesothelioma – case series and review of the literature
Malignant pleural mesothelioma is a rare neoplasm with poor prognosis. Surgical complete resection, which is the only radical therapy available, is only possible in a minority of patients who suffer from a locally advanc...
Dermatofibrosarcoma protuberans (DFSP) – advances in diagnostics and therapy
Dermatofibrosarcoma protuberans is a rare soft tissue sarcoma with a superficial growth. It has an estimated incidence of 4 cases per one million persons per year. DFSP is preferentially located on the trunk. It can appe...